drug · small molecule
OZURDEX
updated 6mo agoby $ABBV AbbVie Inc.🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 5Small molecule drug with a maximum clinical stage of Approval (across all indications), with 75 approved and 174 investigational indications.
targets
Glucocorticoid receptor
all catalysts(0)
nothing on the calendar yet
Trials studying OZURDEX
- phase3To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma
- phase2Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
- phase3Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- phase3A Study in Participants With Relapsed or Refractory Multiple Myeloma for QLS4131
- phase4Lipiflow Treatment Alone vs. Lipiflow + Dextenza Treatment for Dry Eye Disease
- phase3A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- phase3A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
- phase2Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma
News(6)
- Biogen's monoclonal antibody felzartamab wins first global approval in ChinaBiogen’s monoclonal antibody felzartamab was approved in China for the treatment of multiple myeloma. Felzartamab will be available in China for second-line multiple myeloma patients alongside lena…endpoints · 3mo ago
- Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from CelgeneThe clearance of Zenbexus is the first for a group of protein-degrading “CELMoD” medicines that could help Bristol Myers rejuvenate a key drug franchise.biopharma_dive · 3mo ago
- STAT+: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug classThe FDA approved a treatment for advanced multiple myeloma made by Bristol Myers Squibb, marking the debut of a new class of drugs for the blood cancer.stat · 3mo ago
- BMS welcomes new multiple myeloma drug as generics batter current portfolioThe FDA approves Zenbexus just as copycat competitors depress sales of Bristol Myers Squibb’s multiple myeloma drugs Pomalyst and Revlimid, which crashed 71% and 49% year-on-year, respectively, in…biospace · 3mo ago
- Dr Silbermann on Clinical Trial Design Considerations in Multiple MyelomaRebecca Silbermann, MD, MMS, outlines key trial design considerations in multiple myeloma, including supportive care measures and end point selection.onclive · 6mo ago
- FDA tests out ‘real-time’ clinical trials; AbbVie closes in on a KRAS biotechThrough two pioneering studies, Amgen and AstraZeneca will share study data with FDA scientists as it’s accrued. Elsewhere, Lilly inked a gene editing deal and Pfizer reported success for a multipl…biopharma_dive · 6mo ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that